Glucose Lowering through Weight Management (GLoW)

A single-blind, parallel-group, randomised trial to evaluate the clinical and cost-effectiveness of a tailored diabetes education and behavioural weight management programme versus diabetes education, in adults with overweight or obesity and a new diagnosis of type 2 diabetes

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN18399564

Enrollment

576

Registered

2018-07-09

Start date

2018-07-18

Completion date

Unknown

Last updated

2026-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overweight and obesity, type 2 diabetes Nutritional, Metabolic, Endocrine

Interventions

Participants will be randomised to either the tailored diabetes education and behavioural weight management programme or to diabetes education (standard care) in a 1:1 allocation using individual-leve

Eligibility

Sex/Gender

All

Age

18 Years to 120 Years

Inclusion criteria

Inclusion criteria: 1. BMI =25kg/m2 2. Age =18 years 3. Diagnosis of type 2 diabetes within previous 36 months 4. Capable of giving informed consent 5. Have a good understanding of the English language (study materials are not tailored to support non-English language speakers) 6. Willing to be randomised 7. Willing to attend follow up visits at a local participating GP practice

Exclusion criteria

Exclusion criteria: 1. Using insulin 2. Previous/planned bariatric surgery 3. Current/planned pregnancy 4. Current diagnosis of eating disorder 5. Already received a structured diabetes education programme 6. GP considers unsuitable 7. Participation in another structured behaviour change programme for diet and/or physical activity within the past 3 months

Design outcomes

Primary

Measure	Time frame
12 month change from baseline in HbA1c, adjusted for baseline	—

Secondary

Measure	Time frame
1. 6 month change from baseline in HbA1c, adjusted for baseline 2. 6 and 12 month changes from baseline, adjusted for baseline, in body weight, body fat percentage, systolic and diastolic blood pressure, total cholesterol, HDL cholesterol, and LDL cholesterol 3. Probability of achieving good glycaemic control (HbA1c <53 mmol/mol) at 6 and 12 months 4. Probability of achieving remission (HbA1c <48 mmol/mol and without medication for =2 months) at 6 and 12 months 5. Probability of losing =5% and =10% of initial body weight at 6 and 12 months 6. Modelled cardiovascular risk (UKPDS) at 12 months	—

Measure

Time frame

1. 6 month change from baseline in HbA1c, adjusted for baseline 2. 6 and 12 month changes from baseline, adjusted for baseline, in body weight, body fat percentage, systolic and diastolic blood pressure, total cholesterol, HDL cholesterol, and LDL cholesterol 3. Probability of achieving good glycaemic control (HbA1c <53 mmol/mol) at 6 and 12 months 4. Probability of achieving remission (HbA1c <48 mmol/mol and without medication for =2 months) at 6 and 12 months 5. Probability of losing =5% and =10% of initial body weight at 6 and 12 months 6. Modelled cardiovascular risk (UKPDS) at 12 months

—

Countries

England, United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Aug 15, 2026